Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: Seven-year follow up

Internal Medicine

Volumn 49, Issue 15, 2010, Pages 1557-1563

  Yamaguchi, Megu ^a   Yamada, Yuya ^a   Hosokawa, Yoshiya ^a   Iwamoto, Ryuya ^a   Tamba, Sachiko ^a   Ihara, Arisa ^a   Yamamoto, Koji ^a   Hoshida, Yoshihiko ^a   Matsuzawa, Yuji ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Gastrinoma; MEN1; Octreotide; Somatostatin receptor

Indexed keywords

ALFACALCIDOL; BROMOCRIPTINE; CHROMOGRANIN A; FOLLITROPIN; GASTRIN; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; KI 67 ANTIGEN; LEVOTHYROXINE SODIUM; LONG ACTING DRUG; LUTEINIZING HORMONE; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PROLACTIN; PROTON PUMP INHIBITOR; SECRETIN; SOMATOSTATIN RECEPTOR 2;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DUODENUM TUMOR; ENDOSCOPIC BIOPSY; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MENINGITIS; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA AND VOMITING; PANCREAS TUMOR; PRIMARY HYPERPARATHYROIDISM; PROLACTINOMA; PROTEIN EXPRESSION;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTRINOMA; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; OCTREOTIDE; PANCREATIC NEOPLASMS; TIME FACTORS;

EID: 77956201232     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3607     Document Type: Article

References (36)

1. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part II specific NE tumour types. Acta Oncol 43: 626-636, 2004.
2. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of nueroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80: 394-424, 2004.
3. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors. Gut 54: 1-16, 2005.
4. Jensen RT, Niederle B, Mitry E, et al. ENETS guidelines. Gastrinoma (Duodenal and Pancreatic). Neuroendocrinology 84: 173- 182, 2006.
5. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671, 2001.
6. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 80(Suppl 1): 23-27, 2004.
7. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN 1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 243: 465-470, 1998.
8. Challis DR, David R, Shepherd JJ, et al. Enteropancreatic malignancy in multiple endocrine neoplasia type 1: risk factors and pathogenesis. Cancer 83: 428-434, 1998.
9. Pipeleers Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. N Engl J Med 322: 723- 727, 1990.
10. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45: 234-243, 2010.
11. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17: 615-630, 1999.
12. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128: 1668- 1684, 2005.
13. Jensen RT, Gardner JD. Gastrinoma. Raven Press Publishing Co., New York, 1993: 931-978.
14. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108: 1637-1649, 1995.
15. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 15: 2420-2431, 1997.
16. Clark AH, Ajani JA, Benson AB, et al. NCCN clinical practice guidelines in oncology. In: Neuroendocrine tumors. National Comprehensive Cancer, New York, 2009.
17. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94: 331-343, 2002.
18. Rinke A, Müller HH, Schade Brittiger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656- 4663, 2009.
19. Marx S, Spiegal AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129: 484-494, 1998.
20. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 322: 85-87, 1988.
21. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN 1). Q J M 89: 653-669, 1996 (Erratum in: AJM 89: 957-958, 1996).
22. Wilkinson S, Teh B, Davey K, McArdle JP, Young M, Shepherd JJ. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 128: 683-690, 1993.
23. Padberg B, Schröder S, Capella C, Frilling A, Kölppel G, Heitz PU. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch 426: 541-548, 1995.
24. Imamura M, Kanda M, Takahashi K, et al. Clinicopathological characteristics of duodenal microgastrinomas. World J Surg 16: 703-709, 1992.
25. Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg 29: 203-207, 2005.
26. Klöppel G. Tumor biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21: 15-31, 2007.
27. Sholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
28. Brown DC, Gatter KC. Ki-67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
29. Wynick JD, Bloom SR. Clinical review 23: The use of the longacting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 73: 1-3, 1991.
30. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 8: 25-44, 1994.
31. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198, 1999.
32. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15: 966- 973, 2004.
33. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48: 77-85, 1999.
34. Piqueras L, Taché Y, Martinez V. Somatostatin receptor type 2 mediates bombesin-induced inhibition of gastric acid secretion in mice. Am J Physiol 549: 889-901, 2003.
35. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13: 822-840, 2008.
36. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80: 47-50, 2004.